Sandoz loses copycat case concerning blockbuster drug

Sandoz has violated the marketing authorization for a Biogen drug, according to the court. Injunctions are coming, but according to the CEO, the case is based on ”a series of misunderstandings.”
(ARKIV) | Photo: Sebastian Kahnert/AP/Ritzau Scanpix
(ARKIV) | Photo: Sebastian Kahnert/AP/Ritzau Scanpix

Illegal trade in sclerosis medication containing dimethyl fumarate has now resulted in both a ban and a recall order for Sandoz. from the Danish Maritime and Commercial Court. 

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading